María Obdulia Lozano Caballero

María Obdulia Lozano Caballero

Auto-generated profile, based on publicly available information

María Obdulia Lozano Caballero

Hospital Universitario Virgen de la Arrixaca

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2025 in Pain Management
Verified
Journal Article
Closed access
AMAlbert Muñoz-Vendrell
Albert Muñoz-Vendrell
ALAlba López-Bravo
Alba López-Bravo
ALAlmudena Layos-Romero
Almudena Layos-Romero
FAFrancisco J. Alberola-Amores
Francisco J. Alberola-Amores
MCMaría Obdulia Lozano Caballero
María Obdulia Lozano Caballero
O(On behalf of the junior Headache Group of the Spanish Society of Neurology (jGECSEN)
On behalf of the junior Headache Group of the Spanish Society of Neurology (jGECSEN)
Migraine patients over 65 years have been excluded from pivotal anti-CGRP monoclonal antibody trials leaving limited real-life data on effectiveness and safety in this population. This review aims to summarize available evidence on treatment response and safety for older patients. A PubMed and Cochrane Controlled Register of Trials (CENTRAL) search identified studies on anti-CGRP monoclonal antibodies in patients with migraine over 65 up to October 2024. The review focuses on headache outcomes like reduction in monthly migraine days or monthly headache days, response rates (30%, 50%, 75%) and adverse effects of this specific population and/or against placebo, standard care, or younger patients. The quality of evidence was assessed using the GRADE tool. All eligible studies were included, along with additional articles presented narratively. Data from clinical trials and post-hoc analyses show comparable efficacy and safety between older and younger patients. Similarly, early real-life studies support the use of anti-CGRP monoclonal antibodies in patients over 65 years, showing similar response rates, reductions in monthly migraine days and adverse effects. Anti-CGRP monoclonal antibodies should likely be offered to patients over 65 although available evidence remains limited. Further studies analyzing specific data from this subgroup are necessary.